— Why it moved
Why CELZ Stock Quintupled Today — June 30, 2026
An FDA green light to expand a Phase 2 back-pain trial took a $4M biotech from 81 cents to $4.72 in one morning — then it gave three-quarters of the move back by the close.
What moved CELZ stock
Creative Medical Technology is a ~$4.4M biotech developing CELZ-201 for chronic lower back pain. A real catalyst for once: the FDA cleared an expansion of the ADAPT Phase 2 trial, adding a lower-opioid cohort that's already mostly enrolled, on top of 180-day safety data. The company also disclosed about $4.5M raised through a warrant-exercise inducement, so dilution rode in with the good news.
The mechanics
A $4.4M market cap and a 3.4M-share float that normally trades 127K shares a day — point real news at that and you get vertical candles. About 185 million shares changed hands.
CELZ by the numbers
The alert window
Stock Pulse alerted premarket at 8:58 AM at $1.94; the peak $4.72 printed at 9:54 AM — 56 minutes of window, worth 143.2% at the top. It kept running through the opening bell, and the fade started right at the peak and never stopped.
How CELZ's move ended
It closed at $1.41, 27.4% below the alert — peak to close was minus 70%, so holding the round trip turned a 143% gain into a loss. The move took an hour; the unwind took five. The $4.5M warrant inducement means new shares — the rally financed the company, not the holders — and Phase 2 in back pain is years from revenue.
The tell: when the FDA headline arrives welded to a financing, the spike exists to fund the company, and the unwind outlasts the move.